ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK) HKSE

Currency In HKD

AD

Valuation

Market Cap2.16B
Enterprise Value1.71B
P/E Ratio-6.33
PEG Ratio-0.15
Price/Sales Ratio8.91
Price/Book Ratio1.8
Enterprise/Revenue6.06
Enterprise/EBITDA-4.69

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterDecember 31, 2025

Profitability

Profit Margin-1.37
Operating Margin-1.36
AD

Management Effectiveness

Return On Assets-0.2
Return On Equity-0.33

Income Statement

Revenue150.3M
Revenue/Share0.37
Gross Profit134.99M
EBITDA-203.03M
Net Income-212.92M
Diluted EPS-0.51

Balance Sheet

Total Cash1.02B
Total Cash/Share2.39
Total Debt228.12M
Total Debt/Equity0.29
Current Ratio3.83
Book Value Per Share1.86

Price History

52-Week Change-68.91
52-Week High16.8
52-Week Low2.8
Moving Average 50 Days4.13
Moving Average 200 Days6.47

Statistics

Average Volume1.73M
Shares Outstanding420.48M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A
AD